GSK Lapatinib Breast Cancer Filing Delayed; Focus Shifts To Front-Line

Following favorable Phase II interim results, lapatinib clinical efforts will be refocused on the front-line setting, GSK says. Phase III program is ongoing. Firm had planned to submit based on Phase II studies in highly refractory disease, but results were not sufficient for filing.